Generic Name: capmatinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Tabrecta is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with a specific genetic mutation.
Tabrecta targets the MET (mesenchymal-epithelial transition) enzyme, which plays a role in cell development. A gene mutation known as exon 14 skipping leads to greater MET activity, which drives cancer growth.
The GEOMETRY trial showed that Tabrecta shrank tumors in 68% of people with metastatic non-small-cell lung cancer with a confirmed MET exon 14 skipping mutation. The response rate was 41% in a subset of patients who had been previously treated. Tabrecta was first approved in May 2020.
Tabrecta is taken as a tablet twice daily with or without food.
Common adverse reactions include swelling, nausea, vomiting, decreased appetite, fatigue and shortness of breath. Potential serious side effects may include lung inflammation (pneumonitis), liver toxicity and sensitivity to light (photosensitivity), which can lead to severe sunburn. Tabrecta can cause fetal harm if used during pregnancy.
For More Info: https://www.us.tabrecta.com/
Last Reviewed: May 7, 2020